



(51) International Patent Classification:

A61K 31/437 (2006.01) A61K 9/10 (2006.01)
C07D 471/04 (2006.01)

(21) International Application Number:

PCT/US2014/063095

(22) International Filing Date:

30 October 2014 (30.10.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/900,255 5 November 2013 (05.11.2013) US

(71) Applicant: **3M INNOVATIVE PROPERTIES COMPANY** [US/US]; 3m Center, P.O.Box 33427, St. Paul, MN 55133-3427 (US).

(72) Inventors: **BEAURLINE, Joseph**; 3m Innovative Properties Company, 3m Center, P.O. Box 33427, St. Paul, MN 55133-3427 (US). **ELVECROG, James**; 3m Innovative Properties Company, 3m Center, P.O. Box 33427, St. Paul, MN 55133-3427 (US). **VASILAKOS, John**; 3m Innovative Properties Company, 3m Center, P.O. Box 33427, St. Paul, MN 55133-3427 (US).

(74) Agents: **GILLESPIE, Julie Anne** et al.; Astrazeneca Intellectual Property, AstraZeneca R&D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: SESAME OIL BASED INJECTION FORMULATIONS

(57) Abstract: Injectable formulations comprising ethanol, sesame oil, and an Immune Response Modifier compound are disclosed. Methods of making the formulations and methods of using the formulations for treatment of a disease in a subject, e.g., neoplastic disease, comprising injecting the formulations into a subject in need of treatment, are also provided.



WO 2015/069535 A1